Kicovic P M
Minerva Endocrinol. 1989 Jan-Mar;14(1):63-7.
Org OD 14 is a new steroid drug taken orally that appears to act weekly but simultaneously on the estrogens, androgens and progestins. The drug eliminates blood FSH and LH in menopausal women without affecting PRL levels. It also proved more effective than a placebo in controlling hot flushes and related disturbances. The patients treated reveal no reduction in bone mineral content. The incidence of side effects was very low and comparable to the findings in the placebo-treated control group: in particular, there were no changes in body weight, hair distribution of blood pressure. Biochemical studies revealed no alteration in live enzymes, bilirubin, CBG, or cortisol. There was a slight reduction in glucose tolerance but long-term studies revealed no change in the glucoproteins. There was a certain drop in HDL-cholesterol with a tendency to normalise even the long-term and a simultaneous decrease in VLDL and triglycerides which should minimise the risk of cardiovascular pathology. No damaging interference with blood clotting was noted. It may be concluded that oral Org OD 14 is effective and safe for the treatment of menopausal patients.
Org OD 14是一种新的口服类固醇药物,似乎每周起作用一次,但同时作用于雌激素、雄激素和孕激素。该药物可消除绝经后女性血液中的促卵泡生成素(FSH)和促黄体生成素(LH),而不影响催乳素(PRL)水平。在控制潮热及相关不适方面,它也被证明比安慰剂更有效。接受治疗的患者骨矿物质含量没有降低。副作用发生率非常低,与安慰剂治疗的对照组结果相当:特别是体重、毛发分布或血压没有变化。生化研究显示肝酶、胆红素、皮质类固醇结合球蛋白(CBG)或皮质醇没有改变。葡萄糖耐量略有降低,但长期研究显示糖蛋白没有变化。高密度脂蛋白胆固醇(HDL-胆固醇)有一定下降,即使长期来看也有趋于正常的趋势,同时极低密度脂蛋白(VLDL)和甘油三酯减少,这应能将心血管病变的风险降至最低。未发现对血液凝固有破坏性干扰。可以得出结论,口服Org OD 14对治疗绝经患者有效且安全。